Trial Profile
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 04 Jan 2022 Statushas been changed to completed, as per Results published in the JAIDS
- 04 Jan 2022 Results published in the JAIDS
- 04 Apr 2019 Status changed from not yet recruiting to recruiting.